REDWOOD CITY, Calif., Jan. 8, 2016 /PRNewswire/ -- ARMO BioSciences, Inc., a clinical stage developer of immuno-oncology therapeutics, today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 12, 2016 at 3:00 pm Pacific Time.
Peter Van Vlasselaer, PhD, President and CEO of ARMO, will provide an update on the ongoing Phase 1b clinical trial of ARMO's investigational drug AM0010 (PEGylated Interleukin-10) for the treatment of advanced solid tumors and an overview of ARMO's pipeline of cytokine and checkpoint inhibitor immunotherapies. AM0010 has shown activity as a monotherapy and in combination with anti-PD-1 agents in immune-sensitive tumors such as melanoma, renal cell carcinoma, non-small cell lung cancer and others not previously thought to be sensitive to immunotherapy such as colorectal and pancreatic cancers. Dr. Van Vlasselaer will also provide an update on ARMO's plans to initiate registration enabling phase 2/3 studies for AM0010 in multiple solid tumors.
Event: 34th Annual J.P. Morgan Healthcare Conference
Date: Tuesday, January 12, 2016
Time: 03:00 PM - 03:25 PM (Pacific Time)
Location: Westin St. Francis Hotel, San Francisco, CA, Room Elizabethan C
About ARMO BioSciences:
Founded in 2012, ARMO BioSciences is a clinical stage developer of immuno-therapeutics focused on the oncology space and is anchored by its platform molecule AM0010, a PEGylated form of recombinant human IL-10. The company has a robust pipeline with an anti-Programmed Cell Death Protein 1 (PD-1) checkpoint inhibitor and therapeutic cytokines that are complimentary to other immuno-oncology therapeutics and standard of care drugs. ARMO plans to initiate registration enabling phase 2/3 studies for AM0010 in multiple solid tumors.
For more information, please visit www.armobio.com
SOURCE ARMO BioSciences, Inc.